Key Highlights
- Tarsus Pharmaceuticals raised full-year 2026 XDEMVY net-sales guidance to $685 million to $705 million after second-quarter Revenue grew more than 69% to $173.9 million.
- Repligen raised full-year 2026 guidance to revenue of $813 million to $835 million and announced a definitive agreement to acquire BioLife Solutions, deepening its cell-therapy tools exposure.
- BioCryst Pharmaceuticals posted second-quarter Net Income of $78.4 million on total revenue of $218.3 million, with ORLADEYO net revenue of $158.2 million.
- AngioDynamics reported fiscal 2026 net sales of $320.2 million, up 9.4%, with its higher-growth Med Tech segment up 18.4%, though the company remained unprofitable on a GAAP basis.
Healthcare inside the Nasdaq Composite in September 2026 is not one story but several running at once. At the top of the barbell sit companies already turning products into profits. At the other end sit earlier-stage names still spending to prove a market exists. Tarsus Pharmaceuticals (NASDAQ:TARS), Repligen (NASDAQ:RGEN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Lucid Diagnostics (NASDAQ:LUCD) and AngioDynamics (NASDAQ:ANGO) sit at different points along that spectrum, and each reported results earlier this year that let investors judge where they really are.
The macro question hanging over profitless biotech has not changed. Companies that burn cash and rely on future milestones are unusually sensitive to interest rates, because higher discount rates compress the present value of distant cash flows and make dilutive financings more painful.
The Backdrop: Rates, the FDA Calendar and a Return of Deal-Making
The Federal Reserve's next scheduled policy decision falls on September 16, 2026, and the outcome, a cut, a hold, or guidance about the path ahead, matters more to the small-cap, pre-profit end of this group than to the cash-generative names.
That divide is visible across our five. Repligen and BioCryst are profitable on a GAAP basis in their most recent quarters. AngioDynamics is growing its higher-margin Franchise while still posting full-year losses. Tarsus is scaling a single commercial product fast and narrowing its loss. Lucid Diagnostics remains firmly in the build-the-market phase.
Tarsus Pharmaceuticals (NASDAQ:TARS): One Drug, Rising Fast
Tarsus is a commercial-stage eye-care company whose entire story currently rests on XDEMVY, the first FDA-approved treatment for Demodex blepharitis. For the second quarter of 2026, reported August 6, 2026, Tarsus posted total revenue of $173.9 million, essentially all XDEMVY product sales, up more than 69% year over year. The net loss narrowed to $18.6 million, or negative $0.43 per share, from a $20.3 million loss a year earlier. Cash, cash equivalents and marketable securities stood at $449.7 million as of June 30, 2026.
Management raised its full-year 2026 XDEMVY net-sales guidance to a range of $685 million to $705 million, and noted that the number of eye-care professionals prescribing XDEMVY five or more times a week has doubled year over year.
The strength and the risk are the same fact: Tarsus is a one-product company. Its pipeline is trying to change that. The Phase 2 KORE trial in ocular rosacea and the Phase 2 Calliope trial in Lyme disease prevention are both expected to deliver topline data in the first half of 2027.
Repligen (NASDAQ:RGEN): Bioprocessing Recovery, Now With M&A
Repligen sells the picks and shovels of biologic drug manufacturing, filtration, chromatography and analytics used by pharma and biotech customers. After a multi-year destocking hangover across bioprocessing, its 2026 results point to a firmer recovery. In the second quarter, reported July 28, 2026, revenue reached $204 million, up 12% as reported and 13% organically, with gross Margin of 53.9%. GAAP net income was $5.0 million, or $0.09 per diluted share; adjusted diluted EPS was $0.54.
Repligen raised its full-year 2026 guidance to revenue of $813 million to $835 million and adjusted diluted EPS of $2.03 to $2.09. The strategic headline was a definitive agreement to acquire BioLife Solutions, pushing Repligen deeper into cell-therapy tools and adding recurring-revenue exposure.
As a supplier, Repligen is a proxy for the health of its customers' drug pipelines, so accelerating organic growth is an encouraging leading indicator for Biologics Demand generally. The risks are integration execution on the BioLife deal and the reality that tools orders can be lumpy.
BioCryst Pharmaceuticals (NASDAQ:BCRX): Rare Disease, Real Profits
BioCryst has crossed the line that eludes most rare-disease developers: sustained profitability. Its lead product, ORLADEYO, an oral prophylactic for hereditary angioedema, drove second-quarter 2026 total revenue of $218.3 million, reported August 5, 2026, with ORLADEYO net revenue of $158.2 million. The company posted net income of $78.4 million, or $0.30 per diluted share. Cash and investments totaled $354.0 million at quarter-end. Full-year 2026 ORLADEYO guidance was maintained at $625 million to $645 million.
This is a story of concentration risk. ORLADEYO carries the company, so the pipeline determines the next chapter. Navenibart, a longer-acting HAE candidate, completed enrollment in the pivotal ALPHA-ORBIT study, with topline results expected in the third quarter of 2027. BCX17725, a KLK5 inhibitor for Netherton syndrome, is in Phase 1, with data expected by year-end 2026.
Lucid Diagnostics (NASDAQ:LUCD): Early Innings for Esophageal Screening
Lucid Diagnostics is the smallest and earliest-stage name here, a commercial-stage diagnostics company built around EsoGuard, a DNA test run on cells collected with the EsoCheck device to detect esophageal precancer in patients with chronic acid reflux.
The commercial thesis, catching Barrett's esophagus and early cancer in a large at-risk GERD population, is compelling, but the revenue base is still tiny. Lucid reported second-quarter 2026 revenue of about $1.5 million and 2,770 EsoGuard tests processed. Full-year 2025 revenue was $4.71 million. Per one data aggregator, Lucid's market Capitalization was roughly $157 million as of the research date.
This is the archetypal profitless, catalyst-and-reimbursement story. The real drivers are not quarterly revenue but coverage decisions, whether more commercial payers and Medicare pathways reimburse EsoGuard, and Lucid's ability to fund itself until test volumes scale.
AngioDynamics (NASDAQ:ANGO): A Slow Pivot to Higher-Growth Med Tech
AngioDynamics makes interventional devices for oncology and vascular medicine and is midway through reshaping itself around faster-growing, higher-margin Med Tech products. Its fiscal 2026, year ended May 31, 2026, reported July 14, 2026, showed the strategy working at the margin: full-year net sales of $320.2 million, up 9.4%, with the Med Tech segment up 18.4% to $150.0 million and the legacy Med Device segment up 2.5% to $170.2 million. Gross margin was 54.6%. The company remained unprofitable on a GAAP basis, posting a full-year loss of $0.88 per share, but generated $13.2 million of adjusted EBITDA and ended the year debt-free with $53.9 million in cash.
For fiscal 2027, AngioDynamics guided to net sales of $336 million to $341 million, Med Tech growth of 12% to 15%, adjusted EBITDA of $13 million to $16 million, and an adjusted loss per share of negative $0.29 to negative $0.24. Med Tech is growing nicely, but it is not yet large enough to fully offset a nearly flat legacy business.
What Investors Should Watch
The Fed's September 16, 2026 decision will set the tone for the rate-sensitive, pre-profit end of this group, Lucid especially. On company catalysts, BioCryst's BCX17725 Phase 1 data is expected by year-end 2026, the nearest binary event among the five. Tarsus's readouts land in the first half of 2027, and BioCryst's navenibart pivotal data in the third quarter of 2027. Repligen's BioLife Solutions Acquisition needs to close and integrate. AngioDynamics investors should track whether Med Tech growth stays in the guided band and whether the mix shift finally bends the loss line toward breakeven.
A Useful Cross-Section of Nasdaq Healthcare
These five tickers are a useful cross-section of Nasdaq healthcare in September 2026. Repligen and BioCryst show what durable profitability looks like in tools and rare disease. Tarsus shows a single commercial product scaling fast while the loss narrows. AngioDynamics shows a methodical pivot toward higher-growth devices that is not yet finished. Lucid shows the earliest, riskiest end, where the market still has to be built.






Please wait processing your request...